Clerk of the House of Representatives Secretary of the Senate Legislative Resource Center B-106 Cannon Building Washington, DC 20515

Office of Public Records 232 Hart Building Washington, DC 20510

SECRETARY OF THE SE

U2 AUG 13 PM 4:

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name		
The Waldmann Group		
Address	•	
3. Principal Place of Business (if different from line 2)	***************************************	######################################
•	ip (or Country) DC 20004	
City: Washington State/Z 4. Contact Name Telephone	E-mail (optional)	5. Senate ID#
•	·	7003
Daniel R. Waldmann (202) 661-4788	az a v de placé des sentes antique est septembre se ses a second similar ser sentes establists in a second	6. House ID#
7. Client Name Self		
Medical Device Manufacturers Association (MDMA)		3579
9. Check if this filing amends a previously filed version of this s 10. Check if this is a Termination Report □ ⇒ Termination INCOME OR EXPENSES - Complete Either	Date 1	11. No Lobbying
12. Lobbying Firms	13. Organiza	
INCOME relating to lobbying activities for this reporting period was:	EXPENSES relating to lobbying active period were:	
Less than \$10,000 \ \(\overline{\ove	Less than \$10,000 🚨	
\$10,000 or more	\$10,000 or more	
Provide a good faith estimate, rounded to the nearest \$20,000,	accounting method. See instructions t	for description of
of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying	Method A. Reporting amounts us	sing LDA definit
activities on behalf of the client).	Method B. Reporting amounts under section 603 Internal Revenue Code	
	Method C. Reporting amounts u Internal Revenue Co	
Signature Coul R. Woldhur		
Printed Name and Title Daniel R Waldma	ann, Managing Director	



00020262171

Registrant Name	The Waldmann Group	Client Name	Medical Device Manufacturers Association (MDN
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the recngaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.			
15. General issue are	ea code HCR (one	per page)	
16. Specific lobbyin	g issues		
	dical Device Amendments of 20 n of medical devices by the Foo		stration.
17. House(s) of Cor	ngress and Federal agencies	contacted	☐ Check if None
	epresentatives, US Senate.	Ť. ************************************	
18. Name of each n	ndividual who acted as a lob	byist in this issue 1	e area
	Name		Covered Official Position (if applicable)
Daniel R. Waldmann	<u> </u>		***************************************
i th fill think the deal of the analytic real thread to the action of th		***************	
1-41 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2			
************************	······································		nda anna mpangga pagnang pyérmpra nadrawa naddadi ad da dad mana nap pa py sa sa sa kuna puna pyer naga pagna p
110+449444++++++++++++++++++++++++++++++		****************	
**************************************	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~		
4 6 14 14 14 14 14 14 14 14 14 14 14 14 14	ut at 1 00/00-0 10/14 () 100-1-14 (00 -00-0 (+00-0 (********************************	
19. Interest of each f	oreign entity in the specific iss	ues listed on line 1	6 above Check if None
Signature	mil R Wolder	<u></u>	Date 8/12/02
Printed Name and Ti	tle Daniel R. Waldmann, Mai	naging Director	I I

Filing #7aca9356-247f-497a-bfab-2cc1672530c8 - Page 4 of 6	

00020262172

Registrant Name	The Waldmann Group	_ Client Name	Medical Device Manufacturers Association (MDN
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the rengaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.			
15. General issue are	a code MMM (one p	er page)	
16. Specific lobbying	issues		
Competitive bidding	ement for medical devices. g for medical devices. g Modernization and Prescription	Drug Act of 2002	2.
17. House(s) of Cong	gress and Federal agencies co	ontacted	☐ Check if None
	presentatives, US Senate, Co		
	Name]	Covered Official Position (if applicable)
Daniel R. Waldmann			
***************************************	4 1984 4 4 4 5 5 6 4 4 4 4 4 4 4 4 4 4 4 4 4	***************************************	,
**************************************		***************************************	
***************************************		***************************************	**************************************
** \$ \$ ********************************		***************************************	te encompagno and the second contraction of
a ann an 2004 in Ann ann ann an Ann an Ann ann ann an Ann ann a	**************************************		o palaina kala dala are de palai o parto de con del con tele de consest à la lige and con especy de cas albem emb agén l
***************************************	•	· · · · · · · · · · · · · · · · · · ·	
. *************************************)		00.00 0.000.000.000.000.000.000.000.000
19. Interest of each for	eign entity in the specific issue:	s listed on line 16	above
Signature Jer	IR. Walden		Date 8/12/2002
Printed Name and Title	Daniel R. Waldmann, Manag	ging Director	

Filing #7aca9356-247f-497a-bfab-2cc1672530c8 - Page 6 of 6	